dissection in node-positive head and neck squamous cell carcinomas.
INTRODUCTION
Lymph node metastasis is one of the most important prognostic factors for patients with head and neck squamous cell carcinomas (HNSCC).
Although three-weekly high-dose (100mg/m 2 ) cisplatin (three cycles) and radiotherapy has been considered a standard regimen for patients with advanced HNSCC, this protocol is associated with significant acute and late toxicities [1] [2] [3] [4] . Furthermore, the completion rate for this regimen is relatively poor [1] [2] . Therefore, weekly cisplatin at a dose of 40mg/m 2 has been used at our institution since 2006. We reported that weekly cisplatin was easier to manage than three-weekly cisplatin, because patients could be monitored more regularly for toxicity, thereby allowing the schedule to be altered if required [5] . This retrospective study was aimed at assessing the oncologic efficacy of concomitant weekly cisplatin chemoradiotherapy without planned neck dissection (ND) for the control of neck disease. Table 2 . (Table 2) Chemotherapy. Cisplatin was administered at a dose of 40mg/m 2 on weeks 1, 2, 3, 5, 6, and 7 of the radiotherapy. Patients received prophylactic hydration and 5HT3 antagonists plus dexamethasone for anti-emetic prophylaxis. The intended total dose of cisplatin was 240mg/m 2 . The cisplatin dose was modified on a case-by-case basis according to the level of adverse events. In addition, weekly cisplatin was altered to weekly carboplatin [area under the curve (AUC)=1.5] in some cases based on the toxicity. Toxicities were graded using the Common Terminology Criteria for Adverse Events (NCI-CTCAE) Version 3.0.
Radiotherapy. The irradiation plan was 40 Gy in 20 fractions of 2 Gy over four weeks for the primary site and all nodal areas, immediately followed by a boost of 30 Gy in 15 fractions to the primary cancer and metastatic nodal area over an additional three weeks (total dose, 70 Gy).
Post-treatment evaluation and follow-up. There was no intention to perform planned ND patients after the completion of chemoradiotherapy. CT scans were performed 4-8 weeks after the completion of chemoradiotherapy to evaluate nodal response. CT scan criteria of less than 15mm for maximum diameter without any focal abnormalities were reported previously and were applied for evaluation of radiographic complete response (CR) in current study [6, 7] . If residual neck disease was apparent or suspected, we performed early salvage ND. In cases with a radiographic CR based on CT, PET was applied 10-12 weeks after the completion of chemoradiotherapy for reconfirmation. In cases with a CR based both on CT and PET, we took a " wait and see " approach. Patients were usually monitored monthly for the detection of recurrence in the first year, every couple of months in the second year, and every 6 or 12 months thereafter. CT scans were routinely performed once every three months in the first year, and every 6 or 12 months thereafter. If lymph node and/or primary recurrence were observed in the follow-up CT, we performed salvage surgery. When no viable tumor cells were observed in the surgical specimens obtained by ND, nodal metastasis was defined as controlled by weekly cisplatin chemoradiotherapy alone. When salvage ND was performed, we intended to preserve the internal jugular vein, sternocleidomastoid muscle, and the spinal accessory nerve, where possible. The extent of neck dissection included level II, III, IV.
Statistics. The Kaplan-Meier method was applied for survival and control rates using JMP 9.0.2 statistical software (SAS Institute, Cary, NC). Time of interest was the duration from the start of treatment to death or failure.
RESULTS
Chemoradiotherapy. In all patients, a full dose of 70 Gy was achieved.
Weekly cisplatin was administered a median of five times (range 1-6, mean 4.5 times). The median total cisplatin dose was 200mg/m 2 (range 40-240, mean 180mg/m 2 ). Table 3 showed toxicities of chemoradiotherapy. (Table 3) Three patients were switched from concurrent chemotherapy to weekly carboplatin (AUC=1.5) a median of three times (range 2-6, mean 3.7 times) because of renal dysfunction in two patients, and liver dysfunction in one patient.
Salvage surgery. Primary tumors in all patients and lymph node metastases in 20 patients (71%) were evaluated as radiographic CR from the initial evaluation using CT scans. PET was applied in 18 of these 20 patients, and radiographic CR was reconfirmed without abnormal accumulation. In remaining two patients, PET was not used because of patient's wishes.
In eight patients (29%), lymph node metastases were considered to persist according to the initial CT evaluation. These eight patients underwent early salvage ND. In 3 of the 8 patients undergoing early salvage ND, viable tumor cells were observed in the surgical specimens. In the other four patients (14%), recurrent primary tumors were observed at a median of 
DISCUSSION
For patients with HNSCC, lymph node metastasis remains an important prognostic factor. Since the 1970's, planned ND combined with radiotherapy had been considered the standard treatment for these patients [8] . This trend of planned ND was widely used as no modalities for the evaluation of nodal response had yet been developed. Some authors using planned ND reported good nodal control rates and revealed frequent residual nodal metastases in surgical specimens [9] [10] [11] . Therefore they supported the use of planned ND following radiotherapy. However, as more effective chemoradiotherapy regimens were employed, planned ND was no longer considered to be justified for patients who achieved a radiographic CR, according to a recent review [12] .
Since performing ND has some drawbacks, such as like neck stiffness and occasional dysphagia, the general trend has been against the performance of planned ND recently. Therefore, we routinely proceeded without any intention to use planned ND and practiced a " wait and see " approach for patients with a radiographic CR. The nodal control rate for these 52 patients was 91% [15] .
Grabenbauer et.al. reported 97 patients undergoing platin-based chemoradiotherapy (radiotherapy median dose 70 Gy) with CR of the primary disease. Planned NDs were performed for 56 of 97 patients.
Remaining 41 patients did not receive ND and were observed with " wait and see " approach. The nodal control rates for the planned ND patients and " wait and see " patients were 80% and 85%, respectively. It was concluded that there was no clear evidence for the routine clinical use of planned ND [16] .
Although there was no intention to perform planned ND in the current study, the nodal control rate was comparable to recent reports.
Therefore, we consider that the strategy not to perform planned neck dissection and the application of a " wait and see " approach to be acceptable in patients with a radiographic CR.
For the continued use of a " wait and see" approach requires, it is important for nodal response to be evaluated after the completion of chemoradiotherapy. Using CT scans after the completion of chemoradiotherapy was reported to be convenient and helpful in terms of accuracy (negative predictive value: 88.5-94%) [6, 7] . Some authors advocated the use of post-treatment fludeoxyglucose [F18]-PET in determining the presence or absence of residual neck disease [17] [18] [19] . However, the technical and timing issues regarding the use of this modality in the assessment of treatment response during the early post-treatment period remain controversial.
For the reasons mentioned above, we initially use CT scans for the evaluation of nodal response at 4-8 weeks after the completion of chemoradiotherapy initially. For the patients with a radiographic CR based on the CT scans, the addition of PET-CT is suggested at 10-12 weeks post-treatment. If abnormal uptake in the PET-CT is found, we suggest salvage surgery. If no abnormalities are found in the PET-CT, we continue to apply a " wait and see " approach.
Concomitant chemotherapy based on cisplatin and radiotherapy is in widespread use for patients with HNSCC. The standard regimen of concurrent chemotherapy was previously considered to be three-weekly high-dose (100mg/m 2 ) cisplatin (three cycles) [1] [2] [3] . However, a high frequency of significant acute and late toxicities was observed in association with this treatment regimen [1] [2] [3] [4] . Because of these toxicities, it was difficult to apply this regimen at our institution. Therefore, we have used weekly cisplatin regimen at a dose of 40mg/m 2 at our institution since 2006. In our previous study, it was revealed that the application of concomitant weekly cisplatin chemotherapy and radiotherapy was safety and feasible [5] . In the current study, the nodal control rate for patients treated weekly cisplatin chemoradiotherapy was high. Therefore, it is considered that this new regimen appears to be a suitable alternative to three-weekly high dose cisplatin with concomitant radiotherapy from the view points of not only primary disease control but also neck disease control.
CONCLUSIONS
Concomitant weekly cisplatin at a dose of 40mg/m 2 chemoradiotherapy with adequate salvage ND showed a good control rate of not only primary lesion but also neck disease. In the current study, the rate of nodal control by chemoradiotherapy alone and by the overall treatment was found to be 82.0% and 96.3%, respectively. The strategy to avoid planned neck dissection and the application of a " wait and see " approach were considered acceptable in patients with a radiographic CR. 
